GlobeImmune Company Profile (NASDAQ:GBIM)

About GlobeImmune

GlobeImmune logoGlobeImmune, Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company's segment is the business of developing and commercializing various biopharmaceutical products. The Company's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GBIM
  • CUSIP:
Key Metrics:
  • Previous Close: $1.45
  • 50 Day Moving Average: $0.80
  • 200 Day Moving Average: $1.39
  • 52-Week Range: $0.62 - $6.30
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $8.34M
  • Outstanding Shares: 5,751,000
  • Beta: 2.8
Additional Links:
Companies Related to GlobeImmune:

Analyst Ratings

Consensus Ratings for GlobeImmune (NASDAQ:GBIM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for GlobeImmune (NASDAQ:GBIM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for GlobeImmune (NASDAQ:GBIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/15/2016        
5/12/2016Q1($0.27)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GlobeImmune (NASDAQ:GBIM)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for GlobeImmune (NASDAQ:GBIM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for GlobeImmune (NASDAQ:GBIM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/18/2016Augustine LawlorDirectorSell11,000$1.55$17,050.00View SEC Filing  
3/17/2016Daniel J MitchellDirectorSell21,600$1.66$35,856.00View SEC Filing  
3/15/2016Daniel J MitchellDirectorSell130,269$2.26$294,407.94View SEC Filing  
3/11/2016Augustine LawlorDirectorSell16,500$1.60$26,400.00View SEC Filing  
3/10/2016Daniel J MitchellDirectorSell16,400$1.17$19,188.00View SEC Filing  
3/8/2016Augustine LawlorDirectorSell15,010$1.05$15,760.50View SEC Filing  
3/7/2016Daniel J MitchellDirectorSell11,920$1.05$12,516.00View SEC Filing  
3/3/2016Augustine LawlorDirectorSell15,990$1.11$17,748.90View SEC Filing  
3/2/2016Daniel J MitchellDirectorSell17,422$1.02$17,770.44View SEC Filing  
3/1/2016Daniel J MitchellDirectorSell8,799$0.96$8,447.04View SEC Filing  
2/29/2016Augustine LawlorDirectorSell15,000$0.98$14,700.00View SEC Filing  
2/26/2016Daniel J MitchellDirectorSell12,501$1.03$12,876.03View SEC Filing  
2/24/2016Augustine LawlorDirectorSell15,000$1.33$19,950.00View SEC Filing  
2/23/2016Daniel J MitchellDirectorSell22,858$1.42$32,458.36View SEC Filing  
2/22/2016Augustine LawlorDirectorSell5,000$1.43$7,150.00View SEC Filing  
2/19/2016Ventures Vii Lp HealthcareInsiderSell15,000$1.44$21,600.00View SEC Filing  
2/18/2016Daniel J MitchellDirectorSell21,897$1.45$31,750.65View SEC Filing  
2/16/2016Ventures Vii Lp HealthcareMajor ShareholderSell15,000$1.61$24,150.00View SEC Filing  
2/12/2016Daniel J MitchellDirectorSell3,645$1.75$6,378.75View SEC Filing  
2/9/2016Daniel J MitchellDirectorSell7,300$2.05$14,965.00View SEC Filing  
7/8/2014Celgene International IncMajor ShareholderBuy200,000$10.00$2,000,000.00View SEC Filing  
7/8/2014S. Edward TorresDirectorBuy85,000$10.00$850,000.00View SEC Filing  
7/8/2014Timothy C Rodell JrCEOBuy5,000$10.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for GlobeImmune (NASDAQ:GBIM)
DateHeadline
News IconLouisville's GlobeImmune, struggling and down to 2 employees, delists from Nasdaq (NASDAQ:GBIM)
www.dailycamera.com - July 8 at 5:02 AM
News IconGlobeImmune (GBIM) to Delist from the Nasdaq After Weighing Options (NASDAQ:GBIM)
www.economiccalendar.com - July 8 at 5:02 AM
nasdaq.com logoMid-Day Market Update: U.S. Stocks Turn Positive; Nortek Shares Surge Following Acquisition News (NASDAQ:GBIM)
www.nasdaq.com - July 6 at 5:18 PM
streetinsider.com logoAfter-Hours Stock Movers 07/05: (EGLE) (MDVN) (BIIB) Higher; (GBIM) (VTR) (TSLA) Lower (more...) (NASDAQ:GBIM)
www.streetinsider.com - July 6 at 5:18 PM
News IconGlobeImmune shares going off Nasdaq exchange: Stock dives Wednesday (NASDAQ:GBIM)
www.9news.com - July 6 at 5:18 PM
insidermonkey.com logoWhy Tesla, Apple, Alibaba, and Two Other Stocks Are Trending Today (NASDAQ:GBIM)
www.insidermonkey.com - July 6 at 10:49 AM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T (NASDAQ:GBIM)
biz.yahoo.com - July 5 at 4:44 PM
finance.yahoo.com logoGlobeImmune Announces Delisting and Deregistration of Common Stock (NASDAQ:GBIM)
finance.yahoo.com - July 5 at 4:30 PM
News IconGlobeImmune Inc (NASDAQ:GBIM): We Bought The Stock At $1.93 and Sold at $3.30, Amazing Quick profit (NASDAQ:GBIM)
www.marketnewscall.com - June 22 at 9:49 AM
bizjournals.com logoIs this Colorado biotech a takeover target? (NASDAQ:GBIM)
www.bizjournals.com - June 20 at 11:22 AM
News IconGlobeImmune Inc (NASDAQ:GBIM): That’s Why Profit Taking Is Must, Reached Our Target on Friday, Now Down (NASDAQ:GBIM)
www.marketnewscall.com - June 20 at 11:22 AM
News IconGlobeImmune Inc (NASDAQ:GBIM): How Did Our members Trade The Stock? Massive Win In A Single Day (NASDAQ:GBIM)
www.marketnewscall.com - June 20 at 11:22 AM
News IconGlobeImmune Inc (NASDAQ:GBIM): It’s All About Chart For The Momentum Trade (NASDAQ:GBIM)
www.marketnewscall.com - June 19 at 9:28 AM
News IconGlobeImmune Inc (NASDAQ:GBIM): Just Reached Our Target of $3.30 In 24 Hours – Made 70% (NASDAQ:GBIM)
www.marketnewscall.com - June 18 at 9:39 AM
baystreet.ca logoThese Four Companies Are a Must for Your Watchlist, in June (NASDAQ:GBIM)
www.baystreet.ca - June 17 at 5:02 PM
News IconGlobeImmune Inc (NASDAQ:GBIM) And EXACT Sciences Corporation (NASDAQ:EXAS) Are Big Winners Of This Week (NASDAQ:GBIM)
www.marketnewscall.com - June 17 at 5:02 PM
investing.com logoU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.53% (NASDAQ:GBIM)
www.investing.com - June 16 at 5:09 PM
insidermonkey.com logoWhy Korn/Ferry, AMD, Wells Fargo & Two Other Stocks Are in Spotlight Today (NASDAQ:GBIM)
www.insidermonkey.com - June 16 at 1:42 PM
investopedia.com logoMarkets Rally Belatedly To ECB Bazooka (GBIM) (NASDAQ:GBIM)
www.investopedia.com - March 11 at 11:47 AM
News IconGlobeImmune’s CEO cuts own hours, salary to preserve capital (NASDAQ:GBIM)
bizwest.com - February 26 at 10:20 AM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:GBIM)
biz.yahoo.com - February 23 at 4:12 PM
finance.yahoo.com logoGLOBEIMMUNE INC Financials (NASDAQ:GBIM)
finance.yahoo.com - December 8 at 1:18 PM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:GBIM)
biz.yahoo.com - November 13 at 9:12 AM
finance.yahoo.com logoGlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights (NASDAQ:GBIM)
finance.yahoo.com - November 13 at 6:30 AM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 10-Q, Quarterly Report (NASDAQ:GBIM)
biz.yahoo.com - November 13 at 6:15 AM
capitalcube.com logoGlobeImmune, Inc. – Value Analysis (NASDAQ:GBIM) : November 3, 2015 (NASDAQ:GBIM)
www.capitalcube.com - November 3 at 12:08 PM
capitalcube.com logoGlobeImmune, Inc. Earnings Q2, 2015 (NASDAQ:GBIM)
www.capitalcube.com - September 30 at 11:04 AM
finance.yahoo.com logoGlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights (NASDAQ:GBIM)
finance.yahoo.com - August 14 at 6:30 AM
finance.yahoo.com logoGlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options (NASDAQ:GBIM)
finance.yahoo.com - August 13 at 6:30 AM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:GBIM)
biz.yahoo.com - August 4 at 4:29 PM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:GBIM)
biz.yahoo.com - July 17 at 4:31 PM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:GBIM)
biz.yahoo.com - July 13 at 4:12 PM
investors.com logoCan Hepatitis B Be A Blockbuster Bug? (NASDAQ:GBIM)
news.investors.com - July 1 at 8:02 AM

Social

GlobeImmune (NASDAQ:GBIM) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff